Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, gives an overview of the Fms related receptor tyrosine kinase 3 (FLT3) inhibitor landscape for the treatment of acute myeloid leukemia (AML), in particular commenting on the development of novel FLT3 inhibitors. Low specificity and low potency of initial FTL3 inhibitors necessitated the development of the next generation of FLT3 inhibitors, including gilteritinib, quizartinib and crenolanib. Although many FTL3 inhibitors have been approved for treatment, patients often relapse and require further FTL3 inhibitor treatment. Dr Fathi discusses the mechanism of action of a novel irreversible FTL3 inhibitor, FF-10101-01 and describes promising clinical results from a dose-escalation study (NCT03194685) in patients with relapsed/refractory primary or secondary AML. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

свернуть